BGLC
BioNexus Gene Lab·NASDAQ
--
--(--)
--
--(--)
7.03 / 10
Outperform
Fund-flow data reveal a good score of 7.03/10, with Small and Extra-large inflow ratios slightly above 0.5, indicating positive momentum from smaller, speculative accounts. However, overall, block, Medium, and Large trends are negative, hinting at institutional profit-taking. This tug-of-war between retail optimism and institutional caution aligns with the neutral analyst sentiment (no active coverage) and contributes to the Netural overall rating. Investors should monitor flow shifts for confirmation of trend reversals.
Fund Flow Rating
What is the analyst consensus for BGLC?
- BGLC holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 7.03/10 (Outperform).
